Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or California for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to California only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. California (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Vinh-linh Nguyen (NPI 1285603639)

Field	Value
Entity Type	Individual
Organization	Vinh-linh Nguyen
Address	4500 Morning Dr Ste 105
City	Bakersfield
State	CA
ZIP	93306
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	March 17, 2006

Payer Source	Total Paid
Medicare	$11.5M
Medicaid	$0

Key Findings

This provider’s billing mix is characteristic of a high-volume outpatient oncology infusion practice: the top drug codes are monoclonal antibodies and immunotherapies (for example J9271, J9145, J9228) and multiple chemotherapy/infusion administration CPTs appear in the top 25. Specific drug codes with large dollar shares — including J9271 (pembrolizumab), J9145 (daratumumab), J9228 (ipilimumab) and J9299 (nivolumab) — point to routine administration of modern cancer biologics rather than primarily clinic-based procedures. The presence of many infusion add-on and concurrent administration codes (96413, 96417, 96415, 96365, 96367, 96368) reinforces that treatment delivery is largely infusion-centered rather than office evaluation focused.

Revenue is highly concentrated in a small set of therapeutics: the precomputed top-3 Medicare codes by revenue (J9271, J9145, J9228) account for 50.4% of this provider’s total Medicare revenue. Individually those three codes are reported as 19.0% (J9271), 17.1% (J9145), and 14.3% (J9228) of Medicare revenue, so a majority of Medicare dollars are tied to a handful of high-cost oncology agents. That concentration implies financial exposure to utilization shifts, price changes, or coverage policy updates affecting these specific drugs.

Payer mix is effectively single-payer Medicare: lifetime Medicare revenue is $11.5M while there is no Medicaid billing on file. With no Medicaid activity reported, the provider’s outpatient oncology business appears to rely almost entirely on Medicare reimbursement streams, increasing sensitivity to Medicare-specific reimbursement rules and policy changes. Analysts should treat Medicaid-based network or access considerations as not applicable based on the available records.

On national competitive standing this provider is a dominant administrator for multiple oncology drugs: J9145 and J9228 both rank #1 nationally among their peer sets (100th percentile; described as notably above typical national volume), J9271 ranks #16 of 1841 (99th percentile; described as an extreme outlier), and J9299 ranks #2 of 505 (100th percentile; described as an extreme outlier). Several other drug and biosimilar codes (J9047, Q5107, Q5119) are also at or near the top of national rankings (100th percentile or extreme outlier labels), indicating unusually high national-volume activity for these therapies. This pattern is consistent with being a major national outlier for infusion of multiple high-cost oncology agents rather than a modest local participant.

Operational throughput is reflected in unusually high procedural volumes for infusion administration: 96413 ranks #3 of 7514 providers nationally (100th percentile; extreme outlier), 96417 ranks #1 of 3014 (100th percentile; extreme outlier), 96415 ranks #1 of 4959 (100th percentile; extreme outlier), and 96365 ranks #40 of 8873 (100th percentile; extreme outlier). High claims counts tied to these administration codes (for example 96413 with 2.2K claims and 96365 with 1.5K claims as reported) suggest a steady, high-throughput infusion clinic model focused on multi-drug chemotherapy and biologic sessions. These volume signals are important when assessing capacity, staffing, and supply-chain needs.

Clinical vs. evaluation-and-management balance is skewed heavily to drug administration: E&M codes 99214 and 99215 together account for a small fraction of Medicare revenue ($56.8K and $47.6K respectively) compared with multi-million dollar drug revenues (for example $2.2M for J9271 and $2M for J9145). That disparity indicates revenue is driven predominantly by infused therapeutics rather than office visit billings, which has implications for contract design, site-of-care policies, and care management programs. For payer contracting or utilization review, inspections of drug utilization, dosing patterns, and infusion scheduling are likely to be more relevant than traditional E&M utilization controls.

The provider shows active use of biosimilars and a mix of branded agents: biosimilar codes Q5107 (mvasi) and Q5119 (ruxience) appear in the top revenue list with $763.3K (6.6%) and $438.3K (3.8%) of Medicare revenue respectively, and both rank #1 nationally among their peer sets (100th percentile; extreme outlier). The combination of branded immunotherapies and biosimilars in the revenue mix suggests the clinic is incorporating biosimilar options alongside originator biologics, which may influence cost-of-care assessments and biosimilar substitution or steering opportunities. Payers evaluating medical oncology spend should consider both brand and biosimilar flows in any savings or utilization-management strategy.

Tenure data show long standing national enrollment: the provider’s NPI was enumerated on 2006-03-17 (~20 years ago), indicating long-term participation in Medicare. That duration supports interpretation of the high volumes as established practice patterns rather than a recent ramp-up, although recent clinical or referral changes could still explain concentration. For network analyses and continuity of care assessments, this long tenure argues for stable historical claims patterns to review alongside any recent utilization shifts.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

39 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	50,800	$40	$2.2M
J9145	Injection, daratumumab, 10 mg	40,920	$50	$2M
J9228	Injection, ipilimumab, 1 mg	14,300	$120	$1.6M
J9299	Injection, nivolumab, 1 mg	74,400	$20	$1.6M
J9047	Injection, carfilzomib, 1 mg	44,270	$40	$1.6M
Q5107	Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg	33,190	$20	$763.3K
J9264	Injection, paclitaxel protein-bound particles, 1 mg	48,900	$10	$489K
Q5119	Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg	20,870	$20	$438.3K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	2,180	$110	$233.7K
J0897	Injection, denosumab, 1 mg	4,320	$20	$82.1K

Showing 1–10 of 39

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 39 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. California Distribution

Vinh-linh Nguyen — 14 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — California

Full comparison — all codes billed, vs. state median

39 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9145	1	10	40,920	$50	$2M
J9228	1	10	9,100	$120	$1.1M
J9047	1	10	21,340	$40	$850K
J9271	2	140	13,100	$40	$653.5K
J9299	1	40	21,000	$20	$538.5K
J9264	3	10	24,150	$10	$350.2K
Q5107	1	10	2,940	$20	$171.3K
J0897	381	1,030	3,060	$20	$91.4K
Q5119	1	30	1,940	$20	$66.6K
96413	1	620	170	$120	$26.9K

Showing 1–10 of 39

Related Providers

Other providers that share a Tax Identification Number (TIN) with Vinh-linh Nguyen, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Mark Le	FL	Diagnostic Radiology Physician	$10.7M	$0
Nathan Steinle	CA	Retina Specialist (Ophthalmology) Physician	$9.5M	$0
Amiel Moshfegh	CA	Vascular & Interventional Radiology Physician	$7.6M	$0
Alessandro Castellarin	CA	Retina Specialist (Ophthalmology) Physician	$5.4M	$0
Dilsher Dhoot	CA	Retina Specialist (Ophthalmology) Physician	$5.4M	$0
Khaled Tawansy	CA	Ophthalmology Physician	$2.8M	$2.4M
Daniel Learned	CA	Retina Specialist (Ophthalmology) Physician	$5.1M	$0
Dante Pieramici	CA	Retina Specialist (Ophthalmology) Physician	$3.7M	$0
Daniel Taheri	CA	Dermatology Physician	$3.3M	$7.4K
Nallathamby Thayapran	CA	Interventional Cardiology Physician	$3.2M	$0

Nearby Providers

Other providers in the same ZIP code as Vinh-linh Nguyen, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Kern County Hospital Authority	CA	General Acute Care Hospital	$0	$169.4M
County Of Kern	CA	Adolescent and Children Mental Health Clinic/Center	$0	$45.2M
Oh Dmd Inc	CA	General Practice Dentistry	$0	$28.5M
Diego Cavenaghi	CA	Certified Registered Nurse Anesthetist	$209.8K	$0
Theingi Win	CA	Cardiovascular Disease Physician	$131.1K	$0
John Juve	CA	Certified Registered Nurse Anesthetist	$81.1K	$0
Manish Somani Inc	CA	Community/Retail Pharmacy	$45.2K	$25.2K
Maricel Isidro-reighard	CA	Certified Registered Nurse Anesthetist	$65.4K	$0
David Condie	CA	Vascular & Interventional Radiology Physician	$37.5K	$0

Vinh-linh Nguyen — Billing Profile & Reimbursement Data

Sign up for Vinh-linh Nguyen — Billing Profile & Reimbursement Data policy alerts

Vinh-linh Nguyen — Billing Profile & Reimbursement Data

Sign up for Vinh-linh Nguyen — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References